All In Biotech

Drug Trial Radar · NCT05257408

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 381 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

381

Actual

Start

Jun 29, 2022

Primary completion

Mar 31, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Gynecologic Oncology Group
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Conditions

  • Ovarian Neoplasm
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms

Interventions

  • Relacorilant 150 mgDrug

    Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.

  • Nab-paclitaxel 80 mg/m^2Drug

    Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

  • Nab-paclitaxel 100 mg/m^2Drug

    Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 20 months
  2. Overall SurvivalTime frame: Up to 32 months

Locations

116 sites in 14 countries. Site status is shown where the registry gives one.

  • Site 318

    Phoenix, Arizona

  • Site 277

    Tucson, Arizona

  • Site 350

    Irvine, California

  • Site 364

    La Jolla, California

  • Site 150

    Palo Alto, California

  • Site 278

    San Francisco, California

  • Site 014

    San Francisco, California

  • Site 316

    Solvang, California

  • Site 032

    Aurora, Colorado

  • Site 335

    Miami Beach, Florida

  • Site 042

    Weston, Florida

  • Site 009

    Atlanta, Georgia

  • Site 272

    Atlanta, Georgia

  • Site 372

    Gainesville, Georgia

  • Site 291

    Savannah, Georgia

  • Site 315

    Evanston, Illinois

  • Site 314

    Hinsdale, Illinois

  • Site 346

    Urbana, Illinois

  • Site 339

    Indianapolis, Indiana

  • Site 200

    Overland Park, Kansas

  • Site 334

    Overland Park, Kansas

  • Site 279

    Louisville, Kentucky

  • Site 128

    Boston, Massachusetts

  • Site 288

    New Brunswick, New Jersey

  • Site 292

    Albuquerque, New Mexico

  • Site 275

    Flushing, New York

  • Site 298

    Cincinnati, Ohio

  • Site 304

    Cincinnati, Ohio

  • Site 280

    Portland, Oregon

  • Site 317

    Portland, Oregon

  • Site 049

    Portland, Oregon

  • Site 337

    Bethlehem, Pennsylvania

  • Site 127

    Pittsburgh, Pennsylvania

  • Site 276

    Rapid City, South Dakota

  • Site 368

    Germantown, Tennessee

  • Site 281

    Nashville, Tennessee

  • Site 229

    Austin, Texas

  • Site 312

    Bedford, Texas

  • Site 297

    Fort Worth, Texas

  • Site 392

    San Antonio, Texas

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.